BioReliance Implements Newly Adopted OECD Guidelines for Genetic Toxicology Testing After Participating in Regulatory Working Groups
BioReliance, has announced that its full genetic toxicology assay portfolio meets newly ratified universal Organisation for Economic Cooperation and Development (OECD) Guidelines. Scientists from BioReliance were invited to participate in the global OECD expert working groups responsible for updating the guidelines, which were adopted on 26 September 2014, and have worked internally to ensure assays meet the new requirements, including statistical accuracy of negative and positive test results. Customers can benefit from seamless access to the revised guidelines, eliminating any delays that could result as companies seek to comply with the new requirements.
“In response to the updated guidelines, we have been focused on standardising study design and analysis through improved power,” said Scott Hickman, Market Segment Manager for Toxicology at BioReliance. “We have increased the number of cells scored in manual evaluation by as much as 100% across specific assays to enhance their statistical power, and we continue to optimize our processes for automated analysis.”
Since early 2012, expert groups have been working together to achieve clarification related to the update of the test guidelines and the Mutual Acceptance of Data (MAD) agreement. BioReliance scientists took part in these working groups to help define data-driven changes, to upgrade assay design and to interpret results. These efforts resulted in revised test guidelines for the following:
• TG 473: In Vitro Mammalian Chromosomal Aberration Test
• TG 487: In Vitro Mammalian Cell Micronucleus Test
• TG 474: In Vivo Mammalian Erythrocyte Micronucleus Test
• TG 475: In Vivo Mammalian Bone Marrow Chromosomal Aberration Test.
In addition, a new test guideline was also introduced to measure DNA strand breakage:
• TG 489: In Vivo Mammalian Alkaline Comet Assay
While studies using the new guidelines can be initiated immediately, genetic toxicology testing service providers and their customers have a transitional period of 18 months during which they can initiate studies using either the old guidelines or the newly revised guidelines.
“As members of these working groups, our team of scientists felt a responsibility to comply early on, as they recognize the increased power of these enhanced study designs,” said Tim Lawlor, Director of Genetic Toxicology. “We have been diligently working to adjust our laboratory procedures to accommodate the new designs and implement them as the new standard at BioReliance.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance